Search
Innovent Biologics Unveils Latest Clinical Insights on Ocalivimab for Lymphoma Therapy
2 week ago /
Read about 0 minute
Author：小编
At the 18th International Conference on Malignant Lymphoma, Innovent Biologics showcased extensive research outcomes on its proprietary BTK inhibitor, ocalivimab. The presented studies underscored the remarkable efficacy and favorable safety profile of ocalivimab when combined with various therapeutic regimens in treating mantle cell lymphoma, marginal zone lymphoma, and primary central nervous system lymphoma. Notably, the combination therapy of ocalivimab, lenalidomide, and rituximab achieved a total response rate of 100% in newly diagnosed mantle cell lymphoma patients. These groundbreaking findings present novel avenues and promise for the treatment of lymphoma.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
